Effects of Low-Dose Atorvastatin on Hypoxic Response in Statin-Sensitive and Statin-Resistant Cancer Cells
Biological and Pharmaceutical Bulletin · 2025
DOI: 10.1248/bpb.b25-00258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2025. Verfasst von Akihiro Sugiura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Basic Veterinary Science, Joint Graduate School of Veterinary Sciences, Tottori University, 4-101 Koyama-cho, Minami, Tottori 680-8553, J…. Hauptthemen laut MEDLINE: Atorvastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents. Die Arbeit nennt 59 Literaturangaben.
Abstract (Originalsprache)
Statins were initially developed as lipid-lowering agents to reduce the risk of cardiovascular and cerebrovascular diseases. Recently, their anti-tumor effects have gained attention in the context of drug repositioning. However, most in vitro studies have been conducted under normoxic conditions, and limited research has examined their effects under hypoxia. Since hypoxia plays a crucial role in the tumor microenvironment by promoting cancer cell proliferation, epithelial-mesenchymal transition, invasion, metastasis, and drug resistance, evaluating the anti-tumor effects of statins under hypoxic conditions is essential. Additionally, previous in vitro studies have used statin concentrations substantially higher than those observed in the serum during hyperlipidemia treatment, raising concerns about their clinical applicability as anti-tumor agents. Here, we demonstrate that a clinically relevant concentration of atorvastatin (0.1 μM) inhibits the migration and invasion of the statin-sensitive non-small cell lung cancer (NSCLC) cell line HOP-92 under hypoxic conditions, without inducing drug resistance. Furthermore, atorvastatin (0.1-1 μM) reduced the expression of hypoxia-inducible factor-1α (HIF-1α) in the statin-resistant NSCLC cell line NCI-H322M, even though it did not inhibit cell proliferation. Since cancer cell migration and invasion are key processes in distant metastasis, and HIF-1α is a critical transcription factor that regulates metastasis, these findings suggest that statins could be repurposed as anti-metastatic agents for NSCLC, particularly under hypoxic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Basic Veterinary Science, Joint Graduate School of Veterinary Sciences, Tottori University, 4-101 Koyama-cho, Minami, Tottori 680-8553, Japan.
- Department of Biomedical Sciences, School of Biological and Environmental Sciences, Kwansei Gakuin University, 1 Gakuen Uegahara, Sanda, Hyogo 669-1330, Japan.
Zitieren
APA
Sugiura, A., Warita, T., Tashiro, J., Ishikawa, T., & Warita, K. (2025). Effects of Low-Dose Atorvastatin on Hypoxic Response in Statin-Sensitive and Statin-Resistant Cancer Cells. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b25-00258
Vancouver
Sugiura A, Warita T, Tashiro J, Ishikawa T, Warita K. Effects of Low-Dose Atorvastatin on Hypoxic Response in Statin-Sensitive and Statin-Resistant Cancer Cells. Biological and Pharmaceutical Bulletin. 2025. doi:10.1248/bpb.b25-00258
BibTeX
@article{Sugiura2025,
author = {Sugiura, Akihiro and Warita, Tomoko and Tashiro, Jiro and Ishikawa, Takuro and Warita, Katsuhiko},
title = {Effects of Low-Dose Atorvastatin on Hypoxic Response in Statin-Sensitive and Statin-Resistant Cancer Cells},
journal = {Biological and Pharmaceutical Bulletin},
year = {2025},
doi = {10.1248/bpb.b25-00258}
}
EUVIMED